The Medicines and Healthcare products Regulatory Agency (MHRA), alongside the Advertising Standards Authority (ASA) and the General Pharmaceutical Council (GPhC), recently issued a joint warning regarding the promotion of pipeline products, newly licensed prescription-only medicines (POMs), and unlicensed medicines. While ostensibly focused on the weight management sector, this announcement serves as a critical reminder of enduring regulatory principles that apply to all pharmaceutical products, including the nascent medicinal cannabis sector in the UK.

At its core, the warning re-emphasises that advertising must follow regulatory authorisation, not precede it. Rule 12.11 of the CAP Code dictates that medicines must possess an MHRA marketing authorisation before being marketed. Furthermore, Rule 12.12 strictly prohibits the advertising of POMs to the general public. The regulators specifically highlighted concerns around creating waiting lists or generating demand for products still under review or those that are POMs, regardless of the language used (e.g., "oral GLP-1s," "the new weight-loss tablets").

Why This Matters for UK Medicinal Cannabis Operators

For medicinal cannabis operators, founders, and investors in the UK, this announcement resonates deeply, touching on several critical areas:

  • Unlicensed Medicines & Pipeline Products: Most medicinal cannabis products in the UK remain unlicensed 'specials'. While a clinician can prescribe an unlicensed medicine where there is an unmet patient need and it is in the patient’s best interest, the promotion of such products is highly restricted. Operators, including those with Home Office licences for cultivation or manufacture, or WDA(H) holders involved in import and distribution, must be acutely aware that generating public awareness or demand for these products prior to a full marketing authorisation is a direct breach of advertising regulations. This includes any implication of future availability or superiority of specific strains or formulations still in development.

  • Prescription-Only Status: All currently available medicinal cannabis products in the UK are prescription-only. This means any public-facing content that could be construed as advertising to the public is strictly prohibited. This extends beyond explicit calls to action to more subtle forms of promotion, such as patient testimonials that indirectly promote product use, or content on social media that names specific products or implies their efficacy for particular conditions.

  • Responsible Person (RP) Oversight: The MHRA’s stance directly reinforces the critical role of the Responsible Person (RP) within a WDA(H) holding company. RPs are explicitly tasked with ensuring compliance with Good Distribution Practice (GDP), which encompasses advertising regulations related to medicinal products. Boards must ensure their RPs have the authority, resources, and clarity on this matter to prevent non-compliant promotional activities. Investor due diligence should increasingly scrutinise an operator’s marketing practices and RP oversight in this high-risk area.

  • Reputational Risk and Enforcement: Julian Beach, MHRA Executive Director of Healthcare Quality and Access, underscored that "medicinal products are not ordinary consumer goods." This isn't merely a statement; it's a foundational regulatory philosophy. The MHRA, in partnership with other bodies, has demonstrated a willingness to act. The threat of enforcement isn't just financial; it carries significant reputational damage, which can be catastrophic for emerging companies and investor confidence in the sector. Given the sensitivity surrounding medicinal cannabis, any breach could attract disproportionate scrutiny.

  • Investor Perspective: For investors, this adds another layer of regulatory risk to evaluate. Companies that are overly aggressive or careless in their marketing strategies present a higher risk profile. Boards must understand that growth at any cost, especially through non-compliant advertising, is unsustainable and could lead to significant penalties, licence revocation, or even compulsory product recalls.

Medicexum's View

Medicexum advises operators in the UK medicinal cannabis space to treat this warning as a clear directive. The regulators are not just monitoring; they are actively enforcing. The "fast-moving" nature of the sector, as noted by Jess Tye from the ASA, applies equally to cannabis and weight management. Our interpretation is that the MHRA is signalling a broader tightening of controls on promotional activities, especially where companies attempt to bypass the strictures around unlicensed products and POMs.

Practical Takeaways

  1. Review All Marketing Materials: Conduct an immediate, comprehensive review of all public-facing content (websites, social media, print, patient information) for any reference to specific medicinal cannabis products, strains, or formulations that are unlicensed or prescription-only. Remove any content that could be construed as advertising POMs to the public.
  2. Educate Teams: Ensure all marketing, sales, and patient-facing staff understand the severe constraints on promoting medicinal cannabis products. Ignorance of the rules is no defence.
  3. Strengthen RP Governance: Empower your Responsible Person with the authority to veto or modify marketing claims. Implement a robust internal review process for all promotional content involving senior management and the RP.
  4. Focus on Education, Not Promotion: Shift content strategy towards general education about medicinal cannabis, the regulatory framework, chronic conditions, and the patient pathway, without promoting specific products or clinics in a way that falls foul of POM advertising rules.
  5. Be Wary of "Off-Label" Claims: Although cannabis is prescribed for a range of conditions, avoid any claims of efficacy that lack robust, authorised evidence and Marketing Authorisation. This is particularly relevant for CBD products making unauthorised medical claims.
  6. Patience and Compliance: For products in the pipeline aiming for full Marketing Authorisation, resist the urge to pre-promote. Compliant market entry, though slower, is the only sustainable path.

Source: Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management — MHRA / GOV.UK